
Nicole E Benfante

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6082372/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimating patient health in prostate cancer treatment counseling. Prostate Cancer and Prostatic Diseases, 2023, 26, 271-275.	3.9	3
2	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
3	Genetic factors associated with prostate cancer conversion from active surveillance to treatment. Human Genetics and Genomics Advances, 2022, 3, 100070.	1.7	10
4	Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Journal of Urology, 2022, 207, 1222-1226.	0.4	3
5	The Relationship Between PSA and Total Testosterone Levels in Men with Prostate Cancer. Journal of Sexual Medicine, 2022, 19, 471-478.	0.6	5
6	Feasibility of a geriatric comanagement (GERICO) pilot program for patients 75 and older undergoing radical cystectomy. European Journal of Surgical Oncology, 2022, 48, 1427-1432.	1.0	8
7	Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome. Modern Pathology, 2022, 35, 825-835.	5.5	14
8	Urethral Melanoma – Clinical, Pathological and Molecular Characteristics. Bladder Cancer, 2022, 8, 291-301.	0.4	1
9	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
10	A Randomized, Controlled, 3-Arm Trial of Pharmacological Penile Rehabilitation in the Preservation of Erectile Function After Radical Prostatectomy. Journal of Sexual Medicine, 2021, 18, 423-429.	0.6	8
11	Electronic Rapid Fitness Assessment Identifies Factors Associated with Adverse Early Postoperative Outcomes following Radical Cystectomy. Journal of Urology, 2021, 205, 400-406.	0.4	6
12	Prospective Phase II Study to Evaluate Response to Two Induction Courses (12 intravesical) Tj ETQq0 0 0 rgBT /O 197-200.	verlock 10 1.0) Tf 50 307 To 4
13	Limited versus Extended Pelvic Lymph Node Dissection for Prostate Cancer: A Randomized Clinical Trial. European Urology Oncology, 2021, 4, 532-539.	5.4	75
14	Defining the index lesion for potential salvage partial or hemi-gland ablation after radiation therapy for localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 495.e17-495.e24.	1.6	1
15	The Utilization and Impact of Aromatase Inhibitor Therapy in Men With Elevated Estradiol Levels on Testosterone Therapy. Sexual Medicine, 2021, 9, 100378-100378.	1.6	5
16	Shared Medical Appointments for Prostate Cancer Active Surveillance Followup Visits. Urology Practice, 2021, 8, 541-545.	0.5	2
17	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma – An exploratory analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	1.6	3
18	Development and Validation of the Satisfaction Survey for Inflatable Penile Implant (SSIPI). Journal of Sexual Medicine, 2021, 18, 1641-1651.	0.6	14

NICOLE E BENFANTE

#	Article	IF	CITATIONS
19	Value of Partial Nephrectomy for Renal Cortical Tumors of cT2 or Greater Stage: A Risk-benefit Analysis of Renal Function Preservation Versus Increased Postoperative Morbidity. European Urology Oncology, 2020, 3, 365-371.	5.4	10
20	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
21	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
22	Importance of long-term follow-up after endoscopic management for upper tract urothelial carcinoma and factors leading to surgical management. International Urology and Nephrology, 2020, 52, 1465-1469.	1.4	7
23	Bother Associated with Climacturia After Radical Prostatectomy: Prevalence and Predictors. Journal of Sexual Medicine, 2020, 17, 731-736.	0.6	7
24	Routine Postoperative Hemoglobin Assessment Poorly Predicts Transfusion Requirement among Patients Undergoing Minimally Invasive Radical Prostatectomy. Urology Practice, 2020, 7, 299-304.	0.5	2
25	Primary urethral cancer: treatment patterns and associated outcomes. BJU International, 2020, 126, 359-366.	2.5	7
26	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
27	Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. Journal of Urology, 2020, 203, 1122-1127.	0.4	58
28	Risk of Metastasis in Men with Grade Group 2 Prostate Cancer Managed with Active Surveillance at a Tertiary Cancer Center. Journal of Urology, 2020, 203, 1117-1121.	0.4	28
29	Late Recurrences Following Radical Cystectomy Have Distinct Prognostic and Management Considerations. Journal of Urology, 2020, 204, 460-465.	0.4	2
30	Reply by Authors. Journal of Urology, 2020, 203, 1121-1121.	0.4	0
31	Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. Clinical Genitourinary Cancer, 2019, 17, 373-379.e4.	1.9	33
32	Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. Journal of Sexual Medicine, 2019, 16, 872-879.	0.6	27
33	The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. European Urology Focus, 2019, 5, 104-108.	3.1	58
34	Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?. Journal of Urology, 2018, 199, 1502-1509.	0.4	4
35	Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. European Urology Focus, 2018, 4, 100-105.	3.1	14
36	Topography of Prostate Cancer Recurrence After Radiation Therapy: A Detailed Mapping Study of Salvage Radical Prostatectomy Specimens. European Urology, 2018, 73, 488-490.	1.9	20

NICOLE E BENFANTE

#	Article	IF	CITATIONS
37	Intravenous Mannitol Versus Placebo During Partial Nephrectomy in Patients with Normal Kidney Function: A Double-blind, Clinically-integrated, Randomized Trial. European Urology, 2018, 73, 53-59.	1.9	41
38	Renal function recovery after radical nephroureterectomy for upper tract urothelial carcinoma. World Journal of Urology, 2018, 36, 257-263.	2.2	11
39	The association of renal cell carcinoma with gastrointestinal stromal tumors. Journal of Surgical Oncology, 2018, 117, 1716-1720.	1.7	6
40	Obstructive sleep apnea and Fuhrman grade in patients with clear cell renal cell carcinoma treated surgically. World Journal of Urology, 2017, 35, 51-56.	2.2	13
41	Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 532.e7-532.e13.	1.6	25
42	Clinical Outcomes in Patients with Panurothelial Carcinoma Treated with Radical Nephroureterectomy Following Cystectomy for Metachronous Recurrence. Journal of Urology, 2017, 198, 546-551.	0.4	8
43	ls restaging transurethral resection necessary in patients with non-muscle invasive bladder cancer and limited lamina propria invasion?. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e1-603.e5.	1.6	15
44	The difficulty in selecting patients for cytoreductive nephrectomy: An evaluation of previously described predictive models. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 35.e1-35.e5.	1.6	21
45	Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. European Urology Focus, 2017, 3, 590-598.	3.1	31
46	Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. European Urology Focus, 2017, 3, 421-427.	3.1	43
47	Nephrometry scores and perioperative outcomes following robotic partial nephrectomy. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2017, 43, 1075-1083.	1.5	11
48	Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 530.e9-530.e14.	1.6	10
49	Clinical Findings and Treatment Outcomes in Patients with Extraprostatic Extension Identified on Prostate Biopsy. Journal of Urology, 2016, 196, 703-708.	0.4	17
50	Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 259.e1-259.e8.	1.6	56
51	The Prognostic Impact of a Positive Vascular Margin on pT3 Clear Cell Renal Cell Carcinoma. Journal of Urology, 2016, 195, 264-269.	0.4	15
52	Histologic subtype impacts cancer-specific survival in patients with sarcomatoid-variant renal cell carcinoma treated surgically. World Journal of Urology, 2016, 34, 539-544.	2.2	12